Kintara Therapeutics (STU:3DMA) Total Assets : €6.85 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Total Assets?

Kintara Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €6.85 Mil.

During the past 12 months, Kintara Therapeutics's average Total Assets Growth Rate was -70.40% per year. During the past 3 years, the average Total Assets Growth Rate was 64.80% per year. During the past 5 years, the average Total Assets Growth Rate was 46.70% per year.

During the past 13 years, Kintara Therapeutics's highest 3-Year average Total Assets Growth Rate was 447.60%. The lowest was -25.60%. And the median was 52.25%.

Total Assets is connected with ROA %. Kintara Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -172.51%. Total Assets is also linked to Revenue through Asset Turnover. Kintara Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Kintara Therapeutics Total Assets Historical Data

The historical data trend for Kintara Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Total Assets Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Assets

Get a 7-Day Free Trial

3.57

2.61

11.24

15.09

3.67

Kintara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															6.30	3.67	1.38	1.73	6.85

Kintara Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Kintara Therapeutics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	0.675	+	2.998
	=	3.67

Kintara Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	5.448	+	1.402
	=	6.85

Kintara Therapeutics (STU:3DMA) Total Assets Explanation

Total Assets is connected with ROA %.

Kintara Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-7.4	/	( (1.729	+	6.85)	/ 2 )
	=	-7.4	/	4.2895
	=	-172.51 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Kintara Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (1.729	+	6.85)	/ 2 )
=	0	/	4.2895
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Kintara Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines